A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC).

MLA

Tai, W. M., et al. “A Phase Ib Study of Selumetinib (AZD6244, ARRY-142886) in Combination with Sorafenib in Advanced Hepatocellular Carcinoma (HCC).” Annals of Oncology : Official Journal of the European Society for Medical Oncology, vol. 27, no. 12, Dec. 2016, pp. 2210–15. EBSCOhost, https://doi.org/10.1093/annonc/mdw415.

APA

Tai, W. M., Yong, W. P., Lim, C., Low, L. S., Tham, C. K., Koh, T. S., Ng, Q. S., Wang, W. W., Wang, L. Z., Hartano, S., Thng, C. H., Huynh, H., Lim, K. T., Toh, H. C., Goh, B. C., & Choo, S. P. (2016). A phase Ib study of selumetinib (AZD6244, ARRY-142886) in combination with sorafenib in advanced hepatocellular carcinoma (HCC). Annals of Oncology : Official Journal of the European Society for Medical Oncology, 27(12), 2210–2215. https://doi.org/10.1093/annonc/mdw415

Chicago

Tai, W M, W P Yong, C Lim, L S Low, C K Tham, T S Koh, Q S Ng, et al. 2016. “A Phase Ib Study of Selumetinib (AZD6244, ARRY-142886) in Combination with Sorafenib in Advanced Hepatocellular Carcinoma (HCC).” Annals of Oncology : Official Journal of the European Society for Medical Oncology 27 (12): 2210–15. doi:10.1093/annonc/mdw415.